At the news
? BULLISHIMPACT 7/10 8-K filed Jul 16, 2026 at 07:31 ET
Arbutus received ~$178M from the Moderna settlement, filed three international patent lawsuits against Pfizer/BioNTech, and announced a plan to return up to ~$230M to shareholders via share repurchases in Q3 2026. The termination of the RSV agreement with Genevant is a minor procedural item with a $1M fee. The combination of a large cash infusion, ongoing litigation upside, and a substantial buyback plan is a clear positive catalyst.
- Received approximately $178M as Arbutus' share of the $950M noncontingent Moderna settlement payment on July 8, 2026.
- Filed three international patent infringement lawsuits (Canada, UPC) against Pfizer/BioNTech seeking injunctions and monetary damages.
- Announced intent to return up to approximately $230M to shareholders via share repurchases, potentially including a modified Dutch Auction tender offer, expected to commence in Q3 2026 after receipt of a dividend from Genevant parent.
- Terminated the RSV agreement with Genevant in exchange for a $1.0M termination fee.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access